Business

Formycon Successfully Completes Patient Enrollment for the Clinical Development of Its Keytruda(R) Biosimilar Candidate FYB206

Streamlined clinical development program, which no longer requires a Phase III trial, is already in a far advanced stage Last patient enrolled in Dahlia pharmacokinetic (PK) study (Last Patient-In) First patients have completed all 17 treatment ...